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See related research by Lewis et al., https://ccforum.biomedcentral.com/articles/10.1186/s13054-016-1441-z
I read with interest the article by Lewis et al. [1] who
presents a review and meta-analysis of randomized
controlled trials (RCTs) examining the benefit and
harms of prokinetics in patients receiving enteral nu-
trition. They used the Grading of recommendation,
assessment, development, and evaluation (GRADE)
method to assess the quality of evidence for various
clinical outcomes including feeding tolerance, success
of postpyloric placement tubes, pneumonia, mortality,
vomiting, and diarrhoea.
It is important to note that this meta-analysis excluded
studies comparing prokinetics to each other, and
those assessing gastric emptying by pharmacokinetic
(acetaminophen absorption) or isotopic methods. This
may lead to important consequences.
Firstly, all the meta-analysed studies used gastric
residual volume (GRV) as a marker of feeding (in)-
tolerance, with threshold values of 150 to 250 ml for
the definition of intolerance. This may be considered
obsolete since we know nowadays that GRV is a poor
marker of gastric emptying, and the use of GRV for
monitoring enteral nutrition was therefore recently
challenged [2]. Taking this into consideration means that
many patients included in this meta-analysis were falsely
considered intolerant to enteral feeding. This does not
contradict the main conclusions of the article, but instead
it further weakens the already “moderate quality of evi-
dence” that prokinetic agents are effective in improving
feeding intolerance.
Another consequence of the study selection criteria is
the relatively poor number of patients we are left with. In-
deed, after separation of the articles assessing success of
postpyloric tube placement or incidence of pneumonia,
we are left with only five eligible RCTs and a total of 227
patients for evaluation of other major clinical outcomes
including “feeding tolerance”, GRV, vomiting, and diar-
rhoea. Therefore, caution should be taken when interpret-
ing the results. In particular, the increased rate of diarrhoea
did not reach statistical significance, although the incidence
of diarrhoea almost doubled in patients under prokinetic
therapy in the two eligible studies. This is in accordance
with a 40 % (single prokinetic) to 49 % (double prokinetic
therapy) incidence of diarrhoea that was reported in
patients fed enterally [3], suggesting the presence of
digestive malabsorption aggravated by prokinetics in
the critically ill. For intensive care unit (ICU) practi-
tioners, “enteral feeding tolerance” is often assimilated
to “adequate gastric emptying”. Although proper gastric
emptying is a prerequisite for efficient enteral nutrition,
the ultimate goal is to get the nutrients absorbed. In this
regard, we may further question the place of prokinetics,
as these may alter intestinal absorption through poorly
adapted gut motility [4].
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